Sarcouncil Journal of Internal Medicine and Public Health

ISSN(Online): 2945-3674

Volume- 03| Issue- 02| 2024

Research Article **Received:** 21-03-2024| **Accepted:** 15-04-2024 | **Published:** 30-04-2024

Regulatory Challenges in Global Labeling: Compliance Across Multiple Regions

Deepaben Bhavsar

Northeastern University- Boston, MA, USA

Abstract: Regulatory labeling is now recognized as a sensitive aspect of product compliance and patient safety in a highly globalized marketplace in the pharmaceutical, medical device, and consumer goods industries. Nevertheless, the multinational companies experience deep difficulties in their attainment of consistent regulatory compliance, as the requirements of different health authorities in terms of labeling are diverse and even contradictory in various regions. The paper discusses the fact that global labeling is a multi-dimensional issue that impacts the complexity of dealing with divergent regulatory systems, finding a way to harmonize label content using Company Core Data Sheets (CCDS), the process of managing multilingual translations, post-marketing updates, and the adoption of new digital labeling systems. It brings to light operational, legal, and strategic consequences of these challenges and offers a series of systematic recommendations regarding how to have an effective global labeling governance model. Through comparison of traditional and digital labeling strategies, the paper highlights the significance of regulatory intelligence, technological integration, and cross-functional collaboration in ensuring compliance across the world. With the ever-changing regulatory expectations, organizations should be adaptive and patient-centered in labeling to reduce the risk, increase transparency, and facilitate access to the products internationally.

Keywords: Global Labeling Compliance, Regulatory Affairs, CCDS, Pharmaceutical Labeling, Regulatory Intelligence.

INTRODUCTION

Globalization has changed the pharmaceutical, medical device, food, and consumer product industry significantly in the present globalized world, and hence demanded a standard and efficient global labeling approach. Regulatory labeling is the information that is enclosed on a product or that which comes with a product, and it is an extremely critical part of regulatory compliance and health. It conveys important data concerning the usage, dose, warnings, formulation, and side effects of products. However, label development and management in the international markets are extremely difficult processes due to the different and dynamic regulatory conditions in the different parts (Abraham, J. 2004; Bansod, C. R.; Ogbuagu, O. O. *et al.*, 2022). The international labeling laws are created to protect the consumer in that appropriate, full, and easily comprehensible information about the products is provided. Such regulations vary in various jurisdictions such as the United States, the European Union, Japan, and the emerging markets such as Brazil, China, and India. The regulatory frameworks, submission formats, review timelines, and post-approval processes of all regions are appropriately managed as companies expand internationally, and differing laws compel them to comply within legal boundaries to prevent costly delays and safeguard the interests of end consumers (Chisholm, O., & Critchley, H. 2023; Bowman, C. J. *et al.*, 2023; Mueller, M. *et al.*, 2020). Companies operating internationally often face the complex challenge of aligning their global regulatory policies with diverse local requirements; a task that becomes even more demanding when managing products across more than 100 countries. This landscape is further complicated by the need to harmonize labeling, comply with regional regulations, address multilingual demands, and accommodate country-specific healthcare practices. Additionally, emerging regulatory trends such as augmented patient-centric labeling, digital labeling, and real-time updates further add to the complexity of the regulatory landscape (Matsui, R. *et al.*, 2018; Lim, J. C. 2018). The following paper highlights the intricate nature of regulatory labeling compliance in various areas with these emerging dynamics. All of that is connected to the end outcome of consumer safety and regulatory compliance since there is very little that can be done to negotiate between various regional differences in regulatory frameworks to localizing language, and post-marketing surveillance. The following section provides a detailed analysis of the regulatory frameworks across major regions and examines how their disparities impact global labeling operations.

REGULATORY CHALLENGES AND OPPORTUNITIES IN DEVELOPING COUNTRIES' PHARMACEUTICAL SYSTEMS

Following the introduction, the harmonized regulatory frameworks that are used in various countries can be considered as one of the major impediments to international compliance on

***Corresponding Author:** Deepaben Bhavsar

DOI- https://doi.org/10.5281/zenodo.17691578

labeling. These models determine the information disclosed on labels, their format, and the processes and timelines for approving changes, thereby making global standardization of documentation a challenging task. Regulatory agencies are independent, thus interpret the international guidelines regionally, so that this can lead to discrepancies, which can further decelerate the product launch and lead to violations of compliance (Ratanawijitrasin, S., & Wondemagegnehu, E. 2002; EMA, 2020).

The United States Food and Drug Administration (FDA) has a high standard of prescription and over-the-counter medications and prioritizes patient safety through organized forms of labeling on products, such as the Physician Labeling Rule (PLR). In other regions of the European Union, the European Medicines Agency (EMA) enforces harmonized labeling standards through centralized, decentralized, and mutual recognition procedures, while allowing individual member states the autonomy to implement linguistic and national adaptations. Nevertheless, the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan is no exception to the rule of applying culturally-specific terms and format expectations that are rather different than those utilized in the West (Hill, S., & Johnson, K. 2004; Van Roey, J., & Haxaire, M. 2008). China and Brazil have already become giants in regulation in their respective regions; thus, the National Medical Products Administration (NMPA) of China and the ANVISA of Brazil are already in the localization-intensive strategy stages that require full translations and adaptations. This is contrary to the endeavor to harmonize various world standards, such as the one promoted by the International Council on Harmonization (ICH) of Technical Requirements on Pharmaceuticals to be used by Humans, which has been adopted in most non-Western countries, but not all countries have made it mandatory (Cipolla, D. *et al.*, 2019; World Health Organization, 2002). This kind of difference in interpretation of the regulations and their application renders the use of a one-size-fits-all method in global labeling hard. The pharmaceutical and medical equipment companies have to regionalize their documentation and will often have dissimilar labels to satisfy the different demands. Not only does this make doing business more cumbersome, but it also poses the risk of inconsistency, especially in case core safety changes must be propagated to a multitude of regional versions simultaneously (Wiktorowicz, M. *et al.*, 2018; Ramesh, T. *et al.*, 2011). Better, the timeframes of approval of changes in labeling, according to the regulatory policies, are out of this world. In some jurisdictions, the same regulatory dossiers would have to be resubmitted, and minor amendments could require one year or longer before approval, whereas in the FDA, it can be done in a few months. This time gap is the reason why the delivery of essential safety information is postponed in the international markets, and this increases the risk of non-conformance (Handoo, S. *et al.*, 2012; EMA, 2023). To address these concerns, companies tend to invest in dedicated regulatory intelligence teams, which have the mandate of making sure that updates among health authorities are tracked. However, even with these resources, it is not an easy thing to keep track of the regulation changes, especially in the new markets that are not transparent. As a result, companies are already experiencing the same dilemma of flexibility in regulation and standardization that is further addressed in the following section on harmonization of labeling strategies.

THE COMPLEXITY OF HARMONIZATION AND STANDARDIZATION

Due to variations in regulatory frameworks, multinational organizations aim to harmonize their labeling strategies to ensure that core safety and efficacy messages are maintained while accommodating regional differences. However, achieving global label harmonization is not only challenging to implement but also exposes both organizations and countries to operational and legal risks, as shown in Figure 1.

The central principle of harmonization is the company's Company Core Data Sheet (CCDS), a master document that consolidates safety and efficacy information. Ideally, all regional labels are derived from this document. However, aligning local labels with the CCDS can be challenging due to jurisdictional requirements that may conflict with or extend beyond its content (Mueller, M. *et al.*, 2020; CDSCO,; Singh, R. K. *et al.*, 2016). Regulators in certain countries may, for instance, require the inclusion of region-specific epidemiological data, local contraindications, or population-specific warnings that do not apply in other jurisdictions. This compels the companies to leave the global core and make regional changes. Even though these differences are beneficial when it comes to local adoption, it becomes hard to track

Publisher: SARC Publisher

safety cues and to introduce similar changes anywhere on the globe (Lucas, S. *et al.*, 2022; Ayapilla, P. 2023). Other than that, language barrier, culture, and the health literacy level are significant challenges to labeling adaptation within the region. Even minor translation errors can lead to the misinterpretation of critical safety information. Regulatory authorities, such as the EMA and PMDA, often require certified translations and patient information leaflets in local languages, which must be verified for accuracy and clarity (Buckman, S. *et al.*, 2007; Nagaoka, M., & Takamine, T. 2022). The situation becomes even more complex when post-market modifications are required due to newly identified adverse events or updated clinical recommendations. In such cases, global safety departments must coordinate label replacements, manage submission deadlines, and track approval statuses. Failure to implement such systems can lead to regional inconsistencies, regulatory noncompliance, and potential patient safety risks (Swarbrick, J. 2003; Backhouse, J. *et al.*,). Technological advancements, such as labeling management systems and regulatory information management (RIM) platforms, have emerged to streamline and support this process. These systems allow versioning, tracking of changes, and automatic updates on the regulatory changes. They are expensive to implement as they promise, yet in most instances, they need customization to fit internal processes and regulatory requirements (Sugandha, S. *et al.*, 2023).

These considerations will be further elaborated on in the following section, as it will explain the peculiarities and issues of localization of language and translation in global labeling compliance, which further complicates the harmonization process.



Figure 1: Global Labeling Harmonization Framework. A representation of the issues and elements of matching multinational pharmaceutical labels with a centralized Company Core Data Sheet (CCDS) and meeting the regulatory, cultural, and operational needs of the region.

LOCALIZATION AND TRANSLATION ISSUES IN LANGUAGE

In global pharmaceutical compliance, localization and translation present ongoing challenges due to diverse regulatory and linguistic expectations across regions. Each country often requires product information, labeling, and post-marketing documentation to be presented in its official language, following specific terminology, format, and cultural conventions. Translation errors can lead to misinterpretation of safety information, incorrect usage, or delays in regulatory approvals.

Publisher: SARC Publisher

To manage this complexity, companies increasingly rely on centralized systems that can streamline the localization process, track language-specific updates, and ensure consistency across markets. These systems also support the creation of region-specific templates and automate workflows for translation approvals. The need for accurate and compliant language adaptation is especially critical when dealing with complex post-marketing requirements that vary by region, such as those imposed by different health authorities. As regulatory expectations evolve, particularly for high-risk categories like orphan drugs, maintaining precision in language becomes an essential part of global compliance strategy (Le Brun, P. *et al.*, 2023; Fan, M. *et al.*, 2022; Sim, C. *et al.*, 2022).

Regulatory authorities across regions, particularly within the European Union, mandate that labeling for all medicinal products be provided in the official language(s) of each member state where the product is marketed. This multilingual requirement ensures that healthcare professionals and patients across different regions can access accurate, comprehensible, and locally relevant product information. Consequently, high-quality translation and linguistic validation processes are essential for core regulatory documents, including the Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), and packaging components (Van Roey, J., & Haxaire, M. 2008; Handoo, S. *et al.*, 2022; ICH,). Beyond linguistic accuracy, translations must accurately convey medical terminology, dosage instructions, indications, and safety information in alignment with the approved source content. This demands collaboration between subject-matter experts, medical translators, and regulatory reviewers to maintain the scientific and legal integrity of the label.

Localization is a regulated process and plays a critical role in global pharmaceutical labeling compliance. Many countries mandate not only translated label content but also accompanying documentation such as translation certificates, back-translations for verification, and localization audits to ensure alignment with the approved regulatory dossier. For instance, in developing countries, pharmaceutical companies are required to submit both original and translated documents for an official validation process that can take several weeks to months and may involve multiple layers of confirmation and approval from local authorities (World Health Organization. 2002; Ayapilla, P. 2023). To manage these complex requirements, companies have increasingly turned to technological solutions. Tools such as translation memory systems, automated language translation software, and multilingual content management platforms have significantly enhanced the speed and consistency of label translations across various languages and regulatory contexts. These systems help reduce duplication of effort by storing previously approved translations and facilitating re-use across markets.

However, despite these technological advancements, challenges persist. Automated translation tools often fail to capture context-specific medical and regulatory terminology, which can lead to misinterpretation or non-compliance. Even robust translation memory databases can become outdated if not regularly reviewed and synchronized with current regulatory standards, posing a risk of recycling obsolete or incorrect phrasing. These risks highlight the necessity for regular quality checks and regulatory alignment even when using advanced translation tools. Beyond technology, pharmaceutical companies face operational trade-offs when choosing between outsourcing translation services and maintaining in-house linguistic capabilities. Outsourcing can accelerate the localization process and reduce internal workload, but without stringent oversight, it may result in inconsistencies or quality issues, especially when service providers lack regulatory expertise (Buckman, S. *et al.*, 2007). On the other hand, sustaining a dedicated internal team of linguists and regulatory specialists can be prohibitively expensive, each with distinct linguistic and compliance needs. Balancing cost, speed, and quality remains a persistent dilemma for global regulatory teams. Given these complexities, successful localization requires more than just language conversion; it demands a well-integrated strategy that combines linguistic proficiency, regulatory knowledge, and robust quality assurance mechanisms. When executed effectively, localization enhances patient comprehension, promotes adherence, reduces the likelihood of misuse, and builds trust in the healthcare system. As we transition into the next section, we will explore how post-marketing surveillance and periodic regulatory updates further influence labeling compliance and reinforce the ongoing need for localized strategies in pharmaceutical communication.

Publisher: SARC Publisher

POST-MARKETING SURVEILLANCE AND LABEL UPDATES

Another issue of burning global labeling compliance after the concerns of localization is the control of post-marketing surveillance and timely updates to the labels. After a product has successfully passed the green light and gone to market, it is currently in the post-marketing phase, where practical data, negative events, and new findings are more likely to necessitate a revision of the already existing labels, as shown in Figure 2. The core purpose of regulatory affairs teams is to make sure that such updates are replicated in all regional markets in a prompt, regular, and compliant manner (Abraham, J. 2004; Mueller, M. *et al.*, 2020). The jurisdictions are extremely distinct as regards post-marketing surveillance systems. In the United States, the FDA has a system known as the FDA Adverse Event Reporting System (FAERS) whereby safety information is collected and may lead to the change of labels, such as black box warnings or contraindications. The EMA, in turn, has the EudraVigilance system of drug vigilance within the European Economic Area. However, not all countries are well prepared in terms of post-marketing monitoring systems, and even in most developing countries, safety data collection is still informal or unstructured (Lim, J. C. 2018; Wiktorowicz, M. *et al.*, 2018). This gap places multinational companies at the center of collecting, analyzing, and disseminating safety information globally. Once a safety signal is confirmed, the company must evaluate its impact on the Company Core Data Sheet (CCDS) and make necessary updates. These changes should then be communicated to regional affiliates for inclusion in local labels, and in some cases, require resubmission to health authorities (Mueller, M. *et al.*, 2020). This process can result in inconsistencies between regulators in different markets, especially when updates are not synchronized or when certain regions delay or do not adopt necessary changes implemented elsewhere. Moreover, there are also differences in the level and quantity of label modifications following approval by region. Using the example, the FDA and EMA can accept the notification-based modification of certain changes, but other nations need to approve all the label changes at the beginning of the notification, regardless of their severity. This feature significantly slows the process of implementing safety changes at the global level and can put patients at risk of being exposed to old-fashioned tags in service (Ratanawijitrasin, S., & Wondemagegnehu, E. 2002; Lucas, S. *et al.*, 2022).

The administration of such updates is prohibitive. The firms must possess central databases, in which they can track the modifications in labeling, control the timetable of submissions that the regulating organizations demand, and also ensure that all affiliates conform to the corporate policy, not to mention local regulations. They should also store audit trails and documentation as evidence of compliance in the event they are being inspected by the regulatory bodies. Lack of the ability to adequately manage such processes can lead to regulatory fines, product recalls, and loss of publicity (EMA, 2023; Backhouse, J. *et al.*,). Other product information aspects, like promotional applications, training resources, and internet materials, are also modified by label modifications. By making sure that the label is updated, along with all the dependent materials, a regulatory breach can be avoided. Many organizations apply Regulatory Information Management (RIM) systems to process these processes, which, however, are extremely expensive to install, modify, and maintain (Sugandha, S. *et al.*, 2023). Lastly, any delay in translation or in a regulatory review can lead to having various versions of a label that contain conflicting safety data across geographical locations. It not only undermines global compliance but also raises questions of patient safety as far as ethics are concerned (Ramesh, T. *et al.*, 2011; Fan, M. *et al.*, 2022). The digital labeling solutions are gaining momentum in the industry as the need to have real-time safety communication is on the rise. These new technologies offer potential channels for making the updates easier, more accurate, and more responsive to regulation, an issue that is discussed in the next section.

Publisher: SARC Publisher



Figure 2: Post-Marketing Surveillance and Label Update Process

TECHNOLOGICAL INNOVATIONS AND THEIR ROLE IN REGULATORY LABELING COMPLIANCE

As far as the concept of making the traditional labeling management more challenging on the post-marketing stage, the development of the digital labeling technology presents an opportunity to address various regulatory compliance issues. The regulatory climate in the world is more dynamic, and this is why the health authorities and other stakeholders in the industry are becoming more tolerant of digital-based tools, which would be used to facilitate a more efficient flow of dissemination, control, and updating of the labeling content. The term digital labeling is used to describe the use of electronic types and media to supply information concerning products in order to either complement or replace the paper label (Matsui, R. *et al.*, 2023).

The regulators are either initiating or financing frameworks that incorporate digital labeling. Indicatively, the FDA and EMA have initiated pilot programs and guidance programs that will encourage the use of electronic product information (ePI), whereby label material can be sent in real-time by health care providers and the patient. Such a transition will be targeted at minimizing the gap between the changes of labels and their translation into various markets, eliminating the mistakes that could potentially arise during the process of changes in the manual, and enhancing accessibility of information with the help of the dynamic and user-friendly form (EMA, 2020; EMA, 2023). There are a few benefits of digital labeling. The first one is that it allows version control and maintenance of label content in the world. The changes in laws or the safety revision may be disseminated automatically across the electronic platform, which eliminates the chances of regional differences. Second, the online labels can be interactive and user-centered, whereby the providers of health care would search, filter, or customize the available information. This will make it easier to use and assist in improving clinical decision-making (Hill, S., & Johnson, K. 2004). Third, online resources provide the opportunity of multilingual assistance, i.e., automatic display of information in a desired language that a user desires to view. This not only enhances the availability of the multilingual markets, but also helps to minimize the use of printed packaging, which is at times limiting because of the use of space. It can also be integrated with QR codes on the packages of the products that will redirect it to centralized

Publisher: SARC Publisher

databases that store the already available digital labels, and the risk of having out-of-date printed information dumped together is reduced (Lim, J. C. 2018; World Health Organization, 2002).

Despite these advantages, the introduction of digital labeling is not without problems related to it. Digital forms have not been adopted by the regulators in most countries. In the domain of markets, individually and as an example, some of the markets in Europe are allowing the adoption of digital PILs, but others are insisting on hard copy in the local language for each unit of product. Another plausible constraint is the disparity between the digital infrastructure, access to the internet, and digital literacy of the regions, particularly in those countries that are low- and middle-income, and the paper-based system is highly prevalent (Wiktorowicz, M. *et al.,* 2018; Buckman, S. *et al.,* 2007).

Another critical issue is data security and privacy regulations. Strict data protection laws, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States, must be complied with by any platform that collects user data, including digital labeling applications. Compliance with these regulations adds an additional layer of complexity to the implementation of digital solutions (Backhouse, J. *et al.,* ; Fan, M. *et al.,* 2022). As far as operation is concerned, the initiation of a digital labeling system with the current regulatory information management system and pharmacovigilance systems is a procedure that will take time to design and organize. Validation reports, audit trails, and IT security certifications may be mandated by the regulatory authorities in an attempt to promote information integrity and traceability. Also, the companies will have to train the staff and the local subsidiaries on the new workflows on digital and invest in the modernization of the infrastructure that would be scalable and interoperable (Singh, R. K. *et al.,* 2016; Nagaoka, M., & Takamine, T. 2022).

However, the propensity towards digital transformation is increasing more rapidly. The degree of acceptance of digital innovations within the regulatory bodies, i.e., the EU, the US, and the section of Asian-Pacific markets has been on the increase. Other projects like cloud regulatory submissions, electronic Common Technical Document (eCTD) systems, and blockchain supply chain traceability are slowly redefining the manner in which products are labeled and how compliance may be undertaken (Sugandha, S. *et al.,* 2023; Sim, C. *et al.,* 2022). Digital labeling could also be considered a significant element of the future compliance tools based on the prospects of responding to the changes in a timely manner, working with the global versions of labeling, and providing customized and convenient product information. Nonetheless, it will need coordinated regulatory coverage, infrastructural investments, as well as training of the concerned to effectively implement it. After evaluating both traditional and digital labeling approaches, the next section offers practical recommendations for how companies can effectively navigate labeling compliance across different regions worldwide.

Recommendations

Still on the potentials of digital labeling, one can observe that not only technology, but also an appropriate strategic framework will accomplish this. The firms should come up with scalable systems that are swivel-like in order to overcome the complex global labeling regulatory system, which is founded on cross-functional coordination, proactive regulatory intelligence, and quality culture. Centralization of labeling governance is one of the recommendations. It will also include an international labeling controlling agency where each part of the world will be familiarized with the Company Core Data Sheet (CCDS), and meet the needs of the locality. The primary role of this central team is to maintain the master content, manage updates and timelines, and ensure consistency across all versions. Local affiliates act as implementers, handling localization and local regulatory submissions based on the centralized, approved materials.

The other investment that should be made is in Regulatory Information Management (RIM) systems. These websites contain central databases to label documents, the regulatory milestones, regulatory communications made by the health authority, and version histories. RIM tools, in combination with the pharmacovigilance and quality system, also perform risk evaluation and corrective actions in real time. The companies will have to follow regular updates issued by agencies throughout the world and analyze them, since the demands of health authorities will continuously evolve. Timely warnings and policy interpretations offered by subscription-based platforms, regulatory networks, and industry consortia in aiding in predicting changes before they become mandatory can come in handy. To keep abreast of

Publisher: SARC Publisher

compliance risk, companies should allow the labeling processes to integrate such intelligence.

The localization should be located in traditional situations and quality control. The availability of certified translation vendors, the availability of good back-translations, and local reviews would potentially go far in enhancing the linguistic accuracy. The local language reviewers could also be indoctrinated on the regulatory and technical linguistic skillfulness, to make sure that the translation is accurate, besides being culturally pertinent. There will also be a supposed official procedure that will be taken by the companies to address the change of labels once it has been approved. The operations will need to establish the responsibilities, tasks, timetables, and reporting of the safety update. Cohesive update templates, automated processes, and pre-existing review cycles can be used to optimize the process and deliver safety information to all global markets in time. The implementation of the digital labeling should be tested on the traditional one. The organizations are able to choose high-priority markets like the EU or the US and start with them and observe their performance, and adjust their strategies. Feedback should be provided to strengthen regulatory oversight for medical practitioners and patients through a process of trial and error. Meanwhile, companies must be prepared to comply with online audits, data privacy laws, and sustainable planning, as well as adapt to evolving regulatory requirements and technological advancements.

Finally, a culture of compliance and continuous improvement must be fostered. Best practices can be promoted through regular training sessions, cross-functional collaboration, knowledge-sharing platforms, and internal audits, all aimed at ensuring seamless integration and alignment across the entire department. Considering that labeling is a regulatory matter, quality control, medical, pharmacovigilance, and commercial departments, a compromised solution will be necessary to ensure compliance and integrity of products. The guidelines would make organizations prepared to deal with the additional complexity of global labeling regulations.

CONCLUSION

Compliance with global labeling is a complex, multi-dimensional challenge that extends far beyond the label's content. As explored in this paper, multinational companies must navigate inconsistencies arising from conflicting laws and regulations, the intricacies of localization and translation, the requirements of post-marketing surveillance, and the opportunities and risks presented by digital transformation. To make use of such an environment, there must be a tactical compromise between central standardization and local adaptation. Although a harmonization using the CCDS can offer a reference point, there are commonly subtle differences required by the real-life regulations that can reflect a linguistic, clinical, or cultural concern. Businesses must promptly respond to label changes driven by new safety data, with regional harmonization of workflows essential to prevent disparities. Delays in post-marketing compliance updates and inconsistent implementation not only pose regulatory risks but also threaten patient safety. Additionally, forward-looking digital labeling solutions offer the potential to transform how product information is managed and disseminated. Technology cannot, however, solve the systemic challenges without regulatory alignment, infrastructural preparedness, and trust in the stakeholders. The good execution is supported by the good governance model, the investment in digital tools, and consistent correspondence with the regulatory tendencies. Finally, the ability to succeed in global labeling compliance depends on cooperation, transparency, and adherence to the values of patient-centricity. By combining best practices, leveraging technology, and fostering a culture of quality and compliance, companies can effectively manage the current global marketplace while preparing to adapt to future regulatory innovations.

List of Abbreviations

Abbreviation	Full Form
ANVISA	Agência Nacional de Vigilância Sanitária
CCDS	Company Core Data Sheet
EMA	European Medicines Agency
ePI	Electronic Product Information
EU	European Union
FAERS	FDA Adverse Event Reporting System
FDA	Food and Drug Administration

Publisher: SARC Publisher

GDPR	General Data Protection Regulation
HIPAA	Health Insurance Portability and Accountability Act
ICH	International Council for Harmonisation
NMPA	National Medical Products Administration
PIL	Patient Information Leaflet
PLR	Physician Labeling Rule
PMDA	Pharmaceuticals and Medical Devices Agency
QR	Quick Response
RIM	Regulatory Information Management
SmPC	Summary of Product Characteristics
eCTD	Electronic Common Technical Document

REFERENCES

1. Abraham, J. "Pharmaceuticals, the state and the global harmonisation process." *Australian Health Review* 28.2 (2004): 150–160.
2. Bansod, C. R., Hatkar, A. K., & Kawade, R. M. "Role of Regulatory Intelligence in Pharmacovigilance."
3. Ogbuagu, O. O., Mbata, A. O., Balogun, O. D., Oladapo, O., Ojo, O. O., & Muonde, M. "Enhancing biopharmaceutical supply chains: Strategies for efficient drug formulary development in emerging markets." *International Journal of Medical and All Body Health Research* 3.1 (2022): 73–82.
4. Chisholm, O., & Critchley, H. "Future directions in regulatory affairs." *Frontiers in Medicine* 9 (2023): 1082384.
5. Bowman, C. J., Becourt-Lhote, N., Boulifard, V., Cordts, R., Corriol-Rohou, S., Enright, B., et al. "Science-based approach to harmonize contraception recommendations in clinical trials and pharmaceutical labels." *Clinical Pharmacology & Therapeutics* 113.2 (2023): 226–245.
6. Mueller, M., Lewis, D. J., Darisi, V. K. K., & Horn, S. "Current challenges in labelling for generic medicinal products: company core data sheet (CCDS) development and maintenance." *Pharmaceutical Medicine* 34.6 (2020): 381–386.
7. Matsui, R., Yamaguchi, K., Lee, J. J. V., Ting, I., Khairilisani, D., Chang, J., et al. "Survey result for E-labeling initiatives in Asia." *Therapeutic Innovation & Regulatory Science* 57.2 (2023): 251–260.
8. Lim, J. C. "Strengthening health products regulatory systems to enhance access to quality health products in the Asia-Pacific." *Therapeutic Innovation & Regulatory Science* 52.6 (2018): 751–754.
9. Ratanawijitrasin, S., & Wondemagegnehu, E. "Effective drug regulation: A multicountry study." World Health Organization, (2002).
10. EMA, "Electronic product information for human medicines in the EU: Key principles." EMA, (2020).
11. Hill, S., & Johnson, K. "Helpdesk Report: Emerging Challenges and Opportunities in Drug Registration and Regulation in Developing Countries." Health Systems Resource Centre, UK (2004): 1–47.
12. Van Roey, J., & Haxaire, M. "The need to reform current drug registration processes to improve access to essential medicines in developing countries." *Pharmaceutical Medicine* 22.4 (2008): 207–213.
13. Cipolla, D., Shekunov, B., Blanchard, J., Hickey, A., & Gonda, I. "Overview of Brazilian requirements for therapeutic equivalence of orally inhaled and nasal drug products." *AAPS PharmSciTech* 20.6 (2019): 233.
14. World Health Organization, "Annex 9: Guidelines on packaging for pharmaceutical products." *WHO Technical Report Series* No. 902 (2002).
15. Wiktorowicz, M., Moscou, K., & Lexchin, J. "Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence." *Globalization and Health* 14.1 (2018): 86.
16. Ramesh, T., Saravanan, D., & Khullar, P. "Regulatory perspective for entering global pharma markets." *Pharma Times* 43.9 (2011): 15–20.
17. Handoo, S., Arora, V., Khera, D., Nandi, P. K., & Sahu, S. K. "A comprehensive study on regulatory requirements for development and filing of generic drugs globally." *International Journal of Pharmaceutical Investigation* 2.3 (2012): 99.
18. EMA, "Piloting creation of electronic product information (ePI) for EU medicines." EMA, (2023).

Publisher: SARC Publisher

19. CDSCO, "Post Approval Changes in Biological Products: Quality, Safety and Efficacy Documents." CDSCO, (n.d.).
20. Singh, R. K., Kumar, R., & Kumar, P. "Strategic issues in pharmaceutical supply chains: a review." *International Journal of Pharmaceutical and Healthcare Marketing* 10.3 (2016): 234–257.
21. Lucas, S., Ailani, J., Smith, T. R., Abdrabboh, A., Xue, F., & Navetta, M. S. "Pharmacovigilance: reporting requirements throughout a product's lifecycle." *Therapeutic Advances in Drug Safety* 13 (2022): 20420986221125006.
22. Ayapilla, P. "The impact of regional labeling on drug accessibility." Freyr, (2023).
23. Buckman, S., Huang, S.-M., & Murphy, S. "Medical product development and regulatory science for the 21st century: The critical path vision and its impact on health care." *Clinical Pharmacology & Therapeutics* 81.2 (2007): 141–144.
24. Nagaoka, M., & Takamine, T. "E-labeling system in prescription medicines in Japan: measures and perspectives in pharmaceutical industry." *Translational and Regulatory Sciences* 4.1 (2022): 12–19.
25. Swarbrick, J. "Pharmaceutical process validation." In R. A. Nash & A. H. Wachter (Eds.). New York: Marcel Dekker, (2003).
26. Backhouse, J., Rauhe, H., Reed, J. Z., Williams, C., & Berning, J. "Real world pharmaceutical labeling management: From change trigger to implementation." *IQVIA*, (n.d.).
27. Sugandha, S., Choubey, R. R., Gupta, R. K., & Gupta, S. B. "Role of digital transformation and technology adoption in the efficiency of the pharmaceutical industry." *European Chemical Bulletin* 12.5 (2023): 6862–6874.
28. Le Brun, P., Crauste-Manciet, S., Krämer, I., Smith, J., & Woerdenbag, H. (Eds.). "Practical pharmaceutics: An international guideline for the preparation, care and use of medicinal products." 2nd ed. Springer, (2023).
29. Fan, M., Chan, A. Y., Yan, V. K., Tong, X., Lau, L. K., Wan, E. Y., et al. "Postmarketing safety of orphan drugs: A longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018." *Orphanet Journal of Rare Diseases* 17.1 (2022): 3.
30. Sim, C., Zhang, H., & Chang, M. L. "Improving end-to-end traceability and pharma supply chain resilience using blockchain." *Blockchain in Healthcare Today* 5 (2022): 10–30953.
31. ICH, official website: Quality guidelines. *ICH*, (n.d.).

Source of support: Nil; **Conflict of interest:** Nil.

Cite this article as:
Bhavsar, D. " Regulatory Challenges in Global Labeling: Compliance Across Multiple Regions." *Sarcouncil Journal of Internal Medicine and Public Health* 3.2 (2024): pp 43-52.

Publisher: SARC Publisher